<doc>
  <docmeta id="113hr4771ih">
    <bill congress="113" type="hr" number="4771" version="ih"/>
    <revision size="14863" annotations="0" status="complete" id="9" commit-time="2014-06-17T23:19:15Z" committer="mbohmer" doc="113hr4771ih/9.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H64262D40BC88475CB7B3772A22FF4AC9" public-private="public">
	<metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 HR 4771 IH: Designer Anabolic Steroid Control Act of 2014</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. House of Representatives</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2014-05-29</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>H. R. 4771</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20140529">May 29, 2014</action-date>
			<action-desc>
        <sponsor name-id="P000373">Mr. Pitts</sponsor> (for himself and <cosponsor name-id="P000034">Mr. Pallone</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on the <committee-name committee-id="HJU00">Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Controlled Substances Act to more effectively regulate anabolic steroids.</official-title>
	</form>
	<legis-body id="H550032FEDE93424A83A73D320B86FB01" style="OLC">
		<section id="H56FEAAE8071F40898B411CC1F313C49D" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the <quote>
          <short-title>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Designer Anabolic Steroid Control Act of 2014" proposed="true">Designer Anabolic Steroid Control Act of 2014</cato:entity-ref>
          </short-title>
        </quote>.</text>
		</section>
    <section id="H27BF813D8C1C401DB0237C1439EA75D9">
      <enum>2.</enum>
      <header>Amendments to the Controlled Substances Act</header>
			<subsection id="H83BB015182A8468784C6CBDAA0C94F4C">
        <enum>(a)</enum>
        <header>Definitions</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:102/p:41">Section 102(41) of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/802">
            <cato:entity-ref entity-type="uscode" value="usc/21/802/41">21 U.S.C. 802(41)</cato:entity-ref>
          </external-xref>)</cato:entity> is amended—</text>
				<paragraph id="HFC658AFCD2CE423B8EE681D81D247392">
          <enum>(1)</enum>
          <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A">subparagraph (A)</cato:entity-ref>—</text>
					<subparagraph id="H8A161FDA6B344935921EED3CEABC307C">
            <enum>(A)</enum>
            <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A/cl:xlix">clause (xlix)</cato:entity-ref>, by striking <quote>and</quote> at the end;</text>
					</subparagraph>
          <subparagraph id="H31579D98130848548555A7D100B73887">
            <enum>(B)</enum>
            <text>by redesignating <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A/cl:xlx">clause (xlx)</cato:entity-ref> as <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A/cl:lxxvii" proposed="true">clause (lxxvii)</cato:entity-ref>; and</text>
					</subparagraph>
          <subparagraph id="H639E3F06D8A6432496D16CEE34786EBB">
            <enum>(C)</enum>
            <text>by inserting after <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A/cl:xlix">clause (xlix)</cato:entity-ref> the following:</text>
						<quoted-block display-inline="no-display-inline" id="H8C29678092EF442DAB2F8EC744160029" style="OLC">
							<clause id="H11883B03A32449EA8401E924CD91D4B6">
                <enum>(l)</enum>
                <text>5α-Androstan-3,6,17-trione;</text>
							</clause>
              <clause id="HE175C858300C4329AE5B5F7DDDE0411B">
                <enum>(li)</enum>
                <text>Androst-4-ene-3,6,17-trione;</text>
							</clause>
              <clause id="H0A1E6E4268CC454B9367FEF795D0CC19">
                <enum>(lii)</enum>
                <text>Androsta-1,4,6-triene-3,17-dione;</text>
							</clause>
              <clause id="H71FA551CF7974220A964F137BAD5CA6D">
                <enum>(liii)</enum>
                <text>6-bromo-androstan-3,17-dione;</text>
							</clause>
              <clause id="HD71A5A20DAAF4A858D7C1077466BD320">
                <enum>(liv)</enum>
                <text>6-bromo-androsta-1,4-diene-3,17-dione;</text>
							</clause>
              <clause id="H55F04B47619B4AA18D62BB6282F33496">
                <enum>(lv)</enum>
                <text>4-chloro-17α-methyl-androsta-1,4-diene-3,17β-diol;</text>
							</clause>
              <clause id="HA9E1D88155EB4B1F9CBA5F2EF9BDE56E">
                <enum>(lvi)</enum>
                <text>4-chloro-17α-methyl-androst-4-ene-3β,17β-diol;</text>
							</clause>
              <clause id="HBFCC6D84CEE9471D986EC99406A6F4E4">
                <enum>(lvii)</enum>
                <text>4-chloro-17α-methyl-17β-hydroxy-androst-4-en-3-one;</text>
							</clause>
              <clause id="H80CAFB2E1F4A4C7AB5F5CE39A5EBB714">
                <enum>(lviii)</enum>
                <text>4-chloro-17α-methyl-17β-hydroxy-androst-4-ene-3,11-dione;</text>
							</clause>
              <clause id="H00EE1292A64341D3BB76F7FE0C9C2262">
                <enum>(lix)</enum>
                <text>4-chloro-17α-methyl-androsta-1,4-diene-3,17β-diol;</text>
							</clause>
              <clause id="H4B6F46074DF548EF8167202CE32EF7B5">
                <enum>(lx)</enum>
                <text>2α,17α-dimethyl-17β-hydroxy-5α-androstan-3-one;</text>
							</clause>
              <clause id="HA2DEACBCB6224DFAB42CFFE6956C9FFC">
                <enum>(lxi)</enum>
                <text>2α,17α-dimethyl-17β-hydroxy-5β-androstan-3-one;</text>
							</clause>
              <clause id="H8B17F50FC5D84620879ED903D4728F35">
                <enum>(lxii)</enum>
                <text>2α,3α-epithio-17α-methyl-5α-androstan-17β-ol;</text>
							</clause>
              <clause id="HC8898513A5D548D39731046BC2BAF440">
                <enum>(lxiii)</enum>
                <text>[3,2-c]-furazan-5α-androstan-17β-ol;</text>
							</clause>
              <clause id="H01395EBFE2404867AC82B04A5E445BBC">
                <enum>(lxiv)</enum>
                <text>3β-hydroxy-estra-4,9,11-trien-17-one;</text>
							</clause>
              <clause id="H47CA410C36C84E229A45EA767C2C6FF1">
                <enum>(lxv)</enum>
                <text>17α-methyl-androst-2-ene-3,17β-diol;</text>
							</clause>
              <clause id="H8DB7B97063F843959967F7CAB0E1DE68">
                <enum>(lxvi)</enum>
                <text>17α-methyl-androsta-1,4-diene-3,17β-diol;</text>
							</clause>
              <clause id="H7EE2B80241974070B9C5B9812B105CA4">
                <enum>(lxvii)</enum>
                <text>Estra-4,9,11-triene-3,17-dione;</text>
							</clause>
              <clause id="HD47C874AACB142E7814B0683037509EC">
                <enum>(lxviii)</enum>
                <text>18a-Homo-3-hydroxy-estra-2,5(10)-dien-17-one;</text>
							</clause>
              <clause id="H9941829EF22441B59DDBEEDE3705C77D">
                <enum>(lxix)</enum>
                <text>6α-Methyl-androst-4-ene-3,17-dione;</text>
							</clause>
              <clause id="H702359E296CC41CB9BE5ED0DEE9EF8DC">
                <enum>(lxx)</enum>
                <text>17α-Methyl-androstan-3-hydroxyimine-17β-ol;</text>
							</clause>
              <clause id="HDB3A34F40CC5431D859C637CB52E7D0D">
                <enum>(lxxi)</enum>
                <text>17α-Methyl-5α-androstan-17β-ol;</text>
							</clause>
              <clause id="H13EED1CF9387428E959B6ED6BA810D92">
                <enum>(lxxii)</enum>
                <text>17β-Hydroxy-androstano[2,3-d]isoxazole;</text>
							</clause>
              <clause id="H0BF54668F71E497E83E9212A4A82EE1F">
                <enum>(lxxiii)</enum>
                <text>17β-Hydroxy-androstano[3,2-c]isoxazole;</text>
							</clause>
              <clause id="H1D9CB063AE494419BECA4FEA60AC56CF">
                <enum>(lxxiv)</enum>
                <text>4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5α-androstan-17β-ol;</text>
							</clause>
              <clause commented="no" display-inline="no-display-inline" id="HB8A8E9667BFC4589AB54811B9263CE26">
                <enum>(lxxv)</enum>
                <text>[3,2-c]pyrazole-androst-4-en-17β-ol;</text>
							</clause>
              <clause id="H6F41CBDD423E47718D1D2781DF1102DE">
                <enum>(lxxvi)</enum>
                <text>[3,2-c]pyrazole-5α-androstan-17β-ol; and</text>
              </clause>
              <after-quoted-block>; and</after-quoted-block>
            </quoted-block>
					</subparagraph>
        </paragraph>
        <paragraph id="HA8091FB974E248AC83A7D35F893157EE">
          <enum>(2)</enum>
          <text>by adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="H94E4061704874B4C8C39DB119F1F8B94" style="OLC">
						<subparagraph id="H53CB0A7F5EFB40CBBEA9EAFDE3999D85">
              <enum>(C)</enum>
							<clause commented="no" display-inline="yes-display-inline" id="H0D680D46D78B4CA2A266E1A4EA870485">
                <enum>(i)</enum>
                <text>Subject to 
                    
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii" proposed="true">clause (ii)</cato:entity-ref>
                    
                   and the limitations under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i" proposed="true">section 201(i)(6)</cato:entity-ref>, a drug or hormonal substance
			 (other than estrogens, progestins, corticosteroids, and
			 de­hy­dro­epi­an­dros­ter­one) that is not listed in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A">subparagraph (A)</cato:entity-ref> and
			 is
			 derived from, or has a chemical structure substantially similar to, 1 or
			 more anabolic steroids listed in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A">subparagraph (A)</cato:entity-ref> shall be considered to
			 be an anabolic steroid for purposes of this Act if—</text>
								<subclause id="H0D1E14FCB8D24AD9BB84BFDD14E03C05" indent="up1">
                  <enum>(I)</enum>
                  <text>the drug or substance has been created or manufactured with the intent of producing a drug or other
			 substance that either—</text>
									<item id="H895092599E9347C9A2129EE634C182A7">
                    <enum>(aa)</enum>
                    <text>promotes muscle growth; or</text>
									</item>
                  <item id="H3C77FA4906DF485B9887F467F7FFEED1">
                    <enum>(bb)</enum>
                    <text>otherwise causes a pharmacological effect similar to that of testosterone; or</text>
									</item>
                </subclause>
                <subclause id="H953135ED23C54EB090308CC4E132528E" indent="up1">
                  <enum>(II)</enum>
                  <text>the drug or substance has been, or is intended to be, marketed or otherwise promoted in any manner
			 suggesting that consuming it will promote muscle growth or any other
			 pharmacological effect similar to that of testosterone.</text>
								</subclause>
              </clause>
              <clause id="H48F7233ED6484782A2BC3DA35D46A35E" indent="up1">
                <enum>(ii)</enum>
                <text>A substance shall not be considered to be a drug or hormonal substance for purposes of this
			 subparagraph if it—</text>
								<subclause id="H9962F665611A49468C26C25FFD1A38B1">
                  <enum>(I)</enum>
                  <text>is—</text>
									<item id="H259D03473808494BB655CCD9F0B85343">
                    <enum>(aa)</enum>
                    <text>an herb or other botanical;</text>
									</item>
                  <item id="H1C94F539A86742B5BB823E05B4671BD7">
                    <enum>(bb)</enum>
                    <text>a concentrate, metabolite, or extract of, or a constituent isolated directly from, an herb or other
			 botanical; or</text>
									</item>
                  <item id="H2D877B001303461AAB72FA78D7C166D3">
                    <enum>(cc)</enum>
                    <text>a combination of 2 or more substances described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii/scl:I/i:aa" proposed="true">item (aa)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii/scl:I/i:bb" proposed="true">(bb)</cato:entity-ref>; and</text>
									</item>
                </subclause>
                <subclause id="H37DE8FF9E95A4ED49F37D7B56ABA94AE">
                  <enum>(II)</enum>
                  <text>is a dietary ingredient for purposes of the <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                      <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act">Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/301/etseq">21 U.S.C. 301 et
			 seq.</cato:entity-ref>)</cato:entity>.</text>
								</subclause>
              </clause>
              <clause id="HEB3A67A3D3A54214B881D93AC62B6CB7" indent="up1">
                <enum>(iii)</enum>
                <text>In accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:515/ss:a">section 515(a)</cato:entity-ref>, any person claiming the benefit of an exemption or exception
			 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii" proposed="true">clause (ii)</cato:entity-ref> shall bear the burden of going forward with the evidence
			 with respect to such exemption or exception.</text>
              </clause>
            </subparagraph>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
      </subsection>
      <subsection id="H7BB301ECB28D4F98A707AECFE25B7792">
        <enum>(b)</enum>
        <header>Classification authority</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:201">Section 201 of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/811">
            <cato:entity-ref entity-type="uscode" value="usc/21/811">21 U.S.C. 811</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by adding at the end the
			 following:</text>
				<quoted-block display-inline="no-display-inline" id="H866DE47E6DFC4485B194A435D09137C2" style="OLC">
					<subsection id="H778BCCE7409B4DE192895ADB08FA61B1">
            <enum>(i)</enum>
            <header>Temporary and permanent scheduling of recently emerged anabolic steroids</header>
						<paragraph id="H826092DFAB0A496DA59045E1D3B0B885">
              <enum>(1)</enum>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may issue a temporary order adding a drug or other substance to the list of
			 anabolic steroids if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> finds that—</text>
							<subparagraph id="H5259BFC6DB504B52A33FA51536864BF7">
                <enum>(A)</enum>
                <text>the drug or other substance satisfies the criteria for being considered an anabolic steroid under
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/ss:41">section 102(41)</cato:entity-ref> but is not listed in that section or by regulation of the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> as being an anabolic steroid; and</text>
							</subparagraph>
              <subparagraph id="H3BA0DF4790E34097BA33DC26FD793168">
                <enum>(B)</enum>
                <text>adding such drug or other substance to the list of anabolic steroids will assist in preventing the
			 unlawful importation, manufacture, distribution, or dispensing of such
			 drug or other substance.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="HB053562666F94B5CB20FF06B12A2C300">
              <enum>(2)</enum>
              <text>An order issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall not take effect until 30 days after the date of the
			 publication by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> of a notice in the Federal Register of
			 the intention to issue such order and the grounds upon which such order is
			 to be issued. The order shall expire not later than 24 months after the
			 date it becomes effective, except that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may, during
			 the pendency of proceedings under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:5" proposed="true">paragraph (5)</cato:entity-ref>, extend the temporary
			 scheduling order for up to 6 months.</text>
						</paragraph>
            <paragraph id="HD7F59193ACC4478C96849D24DE19C991">
              <enum>(3)</enum>
              <text>A temporary scheduling order issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall be vacated upon the issuance of a
			 permanent scheduling order under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:5" proposed="true">paragraph (5)</cato:entity-ref>.</text>
						</paragraph>
            <paragraph id="HFB8710BB6241475D980B47DB8F665886">
              <enum>(4)</enum>
              <text>An order issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:1" proposed="true">paragraph (1)</cato:entity-ref> is not subject to judicial review.</text>
						</paragraph>
            <paragraph id="H87AB401144F846CEA156B4181F0C6403">
              <enum>(5)</enum>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may, by rule, issue a permanent order adding a drug or other substance to the
			 list of anabolic steroids if such drug or other substance satisfies the
			 criteria for being considered an anabolic steroid under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/ss:41">section 102(41)</cato:entity-ref>.
			 Such rulemaking may be commenced simultaneously with the issuance of the
			 temporary order issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:1" proposed="true">paragraph (1)</cato:entity-ref>.</text>
						</paragraph>
          </subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="H82670C0FCA99463E96ACDAA18CD8EC43">
        <enum>(c)</enum>
        <header>Labeling requirements</header>
				<paragraph id="H9F4C9C5CEBAC49CDADD8036E69B9FBEA">
          <enum>(1)</enum>
          <header>In general</header>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act">Controlled Substances Act</cato:entity-ref> is amended by inserting after <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:305">section 305</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/825">
              <cato:entity-ref entity-type="uscode" value="usc/21/825">21 U.S.C. 825</cato:entity-ref>
            </external-xref>)</cato:entity> the
			 following:</text>
					<quoted-block display-inline="no-display-inline" id="H8A9CE8CCFD2F4CF289CCC8A482C7CF36" style="OLC">
						<section id="HA3115697295D4B80BCA8F0B9F1A44777">
              <enum>305A.</enum>
              <header>Offenses involving false labeling of anabolic steroids</header>
							<subsection id="H5BBB0647F1FF425DAE0540735C754DCE">
                <enum>(a)</enum>
                <header>Unlawful acts</header>
								<paragraph id="H1269834B5DF44BB7B5C737F5AD41AE56">
                  <enum>(1)</enum>
                  <text>It shall be unlawful—</text>
									<subparagraph id="H4101A53E601E4A9B854755067D53C6A5">
                    <enum>(A)</enum>
                    <text>to import into the United States or to export from the United States;</text>
									</subparagraph>
                  <subparagraph id="HDDC0EA37DE264A27B66BB3B5BD2F813B">
                    <enum>(B)</enum>
                    <text>to manufacture, distribute, dispense, sell, or offer to sell; or</text>
									</subparagraph>
                  <subparagraph id="H9B0436602B714E4BBCE1E732B51E6951">
                    <enum>(C)</enum>
                    <text>to possess with intent to manufacture, distribute, dispense, sell, or offer to sell;</text>
                  </subparagraph>
                  <continuation-text continuation-text-level="paragraph">any anabolic steroid, or any product containing an anabolic steroid, unless it bears a label
			 clearly identifying any anabolic steroid contained in such steroid or
			 product by the nomenclature used by the International Union of Pure and
			 Applied Chemistry (IUPAC).</continuation-text>
                </paragraph>
                <paragraph id="H225C2384C5194F2ABCC1A64F9DD24BA6">
                  <enum>(2)</enum>
                  <text>A product that is the subject of an approved application as described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b">section 505(b)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:i">(i)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j">(j)
			 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (
                    <external-xref legal-doc="usc" parsable-cite="usc/21/355">
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/21/355/b">21 U.S.C. 355(b)</cato:entity-ref>
                    </external-xref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/21/355/i">(i)</cato:entity-ref>, or
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/21/355/j">(j)</cato:entity-ref>) is exempt from the International Union of Pure and Applied Chemistry
			 nomenclature requirement of this subsection if such product is labeled in
			 the manner required by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act">Federal Food, Drug, and Cosmetic Act</cato:entity-ref>.</text>
								</paragraph>
              </subsection>
              <subsection id="H5C1BD3FC857E45959530C33345C6D778">
                <enum>(b)</enum>
                <header>Criminal penalties</header>
                <text>Any person who violates <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:305A/ss:a" proposed="true">subsection (a)</cato:entity-ref> knowing, intending, or having reasonable cause to believe,
			 that the substance or product is an anabolic steroid, or contains an
			 anabolic steroid, shall be sentenced to a term of imprisonment of not more
			 than 10 years, a fine not to exceed the greater of that authorized in
			 accordance with the provisions of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/18">title 18, United States Code</cato:entity-ref>, or
			 $500,000 if the defendant is an individual or $2,500,000 if the defendant
			 is other than an individual, or both.</text>
							</subsection>
              <subsection id="H16E195FA144448C4866893A370E43F01">
                <enum>(c)</enum>
                <header>Civil penalties</header>
								<paragraph id="H89BFC0A8894F4B3391276EF71084BECE">
                  <enum>(1)</enum>
                  <text>Any person who violates <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:305A/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall be subject to a civil penalty as follows:</text>
									<subparagraph id="H48B04E6C8FA24653B6710011849C4C35">
                    <enum>(A)</enum>
                    <text>In the case of an importer, exporter, manufacturer, or distributor (other than as provided in
			 
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:305A/ss:c/p:1/sp:B" proposed="true">subparagraph (B)</cato:entity-ref>
                      ), up to $500,000 per violation. For purposes of this
			 subparagraph, a violation is defined as each instance of importation,
			 exportation, manufacturing, or distribution, and each anabolic steroid or
			 product imported, exported, manufactured, or distributed.</text>
									</subparagraph>
                  <subparagraph id="H4A52FA2281A44EE5964AC513A0074FE4">
                    <enum>(B)</enum>
                    <text>In the case of a sale or offer to sell at retail, up to $25,000 per violation. For purposes of this
			 subparagraph, each sale and each product offered for sale shall be
			 considered a separate violation. Continued offers to sell by a person 10
			 or more days after written notice (including through electronic message)
			 to the person by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> or the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall be considered
			 additional violations.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="H0CFB05C5A76442C287AE93C825A2FB3E">
                  <enum>(2)</enum>
                  <text>In this subsection, the term <term>product</term> means a discrete article, either in bulk or in finished form prepared for sale. A number of
			 articles, if similarly packaged and bearing identical labels, shall be
			 considered as one product, but each package size, form, or differently
			 labeled article shall be considered a separate product.</text>
								</paragraph>
              </subsection>
              <subsection id="H8EA38AFF3B824385A1767ADA2DA361F0">
                <enum>(d)</enum>
                <header>Identification and publication of list of products containing anabolic steroids</header>
								<paragraph id="H5BCA138E5C634EDAA0DCE548B271A231">
                  <enum>(1)</enum>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may, in his discretion, collect data and analyze products to determine whether
			 they contain anabolic steroids and are properly labeled in accordance with
			 this section. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may publish in the Federal Register or
			 on the website of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1524" entity-type="federal-body">Drug Enforcement Administration</cato:entity-ref> a list of products
			 that he has determined, based on substantial evidence, contain an anabolic
			 steroid and are not labeled in accordance with this section.</text>
								</paragraph>
                <paragraph id="H6527712D68D14EEF98668A970FACB43A">
                  <enum>(2)</enum>
                  <text>The absence of a product from the list referred to in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:305A/ss:d/p:1/sp:" proposed="true">paragraph (1)</cato:entity-ref> shall not constitute evidence
			 that the product does not contain an anabolic steroid.</text>
                </paragraph>
              </subsection>
            </section>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
        <paragraph id="H2BF28F2F03E54AF682A645BFEC639C71">
          <enum>(2)</enum>
          <header>Table of contents</header>
          <text>The table of contents for the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Comprehensive Drug Abuse Prevention and Control Act of 1970">Comprehensive Drug Abuse Prevention and Control Act of 1970</cato:entity-ref> is
			 amended by inserting after the item relating to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Comprehensive Drug Abuse Prevention and Control Act of 1970/s:305">section 305</cato:entity-ref> the following:</text>
					<quoted-block display-inline="no-display-inline" id="H2D5F15007B86495AA05A4EA599920A45" style="OLC">
						<toc>
							<toc-entry bold="off" level="section">Sec. 305A. Offenses involving false labeling of anabolic steroids.</toc-entry>
            </toc>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
      </subsection>
    </section>
  </legis-body>
</bill>
</doc>